Katsuyoshi Matsuoka

Katsuyoshi Matsuoka

Sakura, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 249 publications

Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study.

Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study.

Journal: The Lancet regional health. Western Pacific

Published: June 03, 2026

Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).

Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).

Journal: Journal of gastroenterology

Published: April 10, 2026

The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence.

The trajectory of inflammatory bowel disease in east and southeast Asia: transitioning from acceleration in incidence to compounding prevalence.

Journal: The lancet. Gastroenterology & hepatology

Published: February 18, 2026

Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis.

Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis.

Journal: Journal of Crohn's & colitis

Published: February 09, 2026

Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study.

Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study.

Journal: Intestinal research

Published: January 23, 2026

Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.

Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.

Journal: Journal of gastroenterology

Published: December 26, 2025

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.

Journal: Journal of gastroenterology and hepatology

Published: December 13, 2025

Prevalence and Outcomes of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: A Multinational Study Across Asia.

Prevalence and Outcomes of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: A Multinational Study Across Asia.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 16, 2025

Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study.

Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study.

Journal: Crohn's & colitis 360

Published: September 10, 2025

Impact of filgotinib on health-related quality of life over 3 years in Japanese patients with ulcerative colitis: a post hoc analysis of the SELECTION and SELECTION long-term extension trials.

Impact of filgotinib on health-related quality of life over 3 years in Japanese patients with ulcerative colitis: a post hoc analysis of the SELECTION and SELECTION long-term extension trials.

Journal: Intestinal research

Published: September 09, 2025

Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials.

Guselkumab efficacy and safety in East Asian participants with moderately to severely active Crohn's disease: subgroup analysis of the phase 3 GALAXI 2 and GALAXI 3 trials.

Journal: Intestinal research

Published: July 22, 2025

Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.

Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.

Journal: Journal of gastroenterology

Published: June 20, 2025

Showing 1-12 of 249

Last Updated: 09/26/2026